Long-Term Cost-Effectiveness Analysis of Etanercept and Adalimumab for Plaque Psoriasis not Associated with Arthritis

[1]  L. Sawyer,et al.  Assessment and management of psoriasis: summary of NICE guidance , 2012, BMJ : British Medical Journal.

[2]  J. Mauskopf,et al.  Cost-effectiveness of treatment with etanercept for psoriasis in Sweden , 2012, The European Journal of Health Economics.

[3]  A. Gottlieb,et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. , 2011, Journal of the American Academy of Dermatology.

[4]  C. Lereun,et al.  A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis , 2010, The British journal of dermatology.

[5]  M. Augustin,et al.  Cost-Effectiveness of Biological Therapy in Remission Induction of Moderate to Severe Plaque Psoriasis , 2010, Dermatology.

[6]  C. Ferrándiz,et al.  [Efficiency of biologic agents in the treatment of moderate to severe psoriasis]. , 2009, Actas dermo-sifiliograficas.

[7]  C. Ferrándiz,et al.  Eficiencia de los agentes biológicos en el tratamiento de la psoriasis moderada-grave , 2009 .

[8]  L. Naldi,et al.  European S3‐Guidelines on the systemic treatment of psoriasis vulgaris , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  L. Braathen,et al.  Cost-effectiveness of biologics for moderate-to-severe psoriasis from the perspective of the Swiss healthcare system. , 2009, European journal of dermatology : EJD.

[10]  E. Loveman,et al.  Adalimumab for the treatment of psoriasis. , 2009, Health Technology Assessment.

[11]  S. Feldman,et al.  Economic evaluation of systemic therapies for moderate to severe psoriasis , 2009, The British journal of dermatology.

[12]  L. Kircik,et al.  Anti-TNF agents for the treatment of psoriasis. , 2009, Journal of drugs in dermatology : JDD.

[13]  J. M. Carrascosa,et al.  Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos , 2009 .

[14]  J. Fowler,et al.  The impact of psoriasis on health care costs and patient work loss. , 2008, Journal of American Academy of Dermatology.

[15]  Steven R Feldman,et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. , 2008, Journal of the American Academy of Dermatology.

[16]  A. Kimball,et al.  Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  S. Feldman,et al.  Does cost‐effectiveness play a role in clinical trials? , 2007, Dermatologic therapy.

[18]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[19]  E. Berardesca,et al.  Cost‐effectiveness analysis of TNF‐α blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health‐care system , 2010, Dermatologic therapy.

[20]  J. Carrascosa,et al.  [Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents]. , 2009, Actas dermo-sifiliograficas.

[21]  S. Feldman,et al.  Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. , 2008, Journal of the American Academy of Dermatology.

[22]  S. Feldman,et al.  Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. , 2008, Current medical research and opinion.